Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).
Layoffs are also under consideration as part of broader cost-cutting measures. New CEO Mike Doustdar, who took the helm in August, told Danish broadcaster TV2 that he will explore further savings.
